Kazuo Kasahara
Kanazawa University
CancerInternal medicineRadiologySurgeryPathologyOncologyImmunologyAsthmaLung cancerChemotherapyLungEpidermal growth factor receptorGefitinibAdenocarcinomaCarboplatinNon small cellAnesthesiaCancer researchMedicineGastroenterology
282Publications
26H-index
3,131Citations
Publications 280
Newest
#1Yuko Waseda (University of Fukui)H-Index: 13
#2Masahide YasuiH-Index: 20
Last. Tamotsu Ishizuka (University of Fukui)H-Index: 36
view all 16 authors...
BACKGROUND Drug-induced pneumonia (d-pneumonia) and bacterial pneumonia (b-pneumonia) are often difficult to differentiate; therefore, this study examined the possibility of differentiating them using serum biomarkers. METHODS The study included 22 and 16 patients diagnosed with b- and d-pneumonia, respectively, at our institution or affiliated institutions. For d-pneumonia, the causative drug was minocycline hydrochloride in four patients, gefitinib in two patients, nivolumab in two patients, p...
Source
#1M D Mohiuddin (Kanazawa University)
#2Kazuo Kasahara (Kanazawa University)H-Index: 26
BACKGROUND/AIM Non-small-cell lung cancer (NSCLC) remains a significant cause of death despite the recent introduction of several improved therapeutics. Pemetrexed disodium heptahydrate (pemetrexed) is currently available in combination with a platinum derivative for patients with advanced non-squamous NSCLC for first-line treatment, and as a single agent for second-line treatment. However, the mechanisms underlying its anticancer activities are still not well understood. In this study, we evalu...
Source
#1Hidehito HorinouchiH-Index: 21
#2Naoyuki NogamiH-Index: 27
Last. Takayasu Kurata (Kansai Medical University)H-Index: 35
view all 13 authors...
Pembrolizumab plus pemetrexed-platinum significantly improved overall survival (OS) and progression-free survival (PFS) with manageable safety versus placebo plus pemetrexed-platinum in patients with previously untreated metastatic nonsquamous non-small-cell lung cancer (NSCLC) without EGFR/ALK alterations in the global, randomized, double-blind, phase 3 KEYNOTE-189 study. We present results of Japanese patients enrolled in the KEYNOTE-189 global and Japan extension studies. Patients were random...
Source
#1K. Ide (Kanazawa University)
#1Kentaro Ide (Kanazawa University)
Last. Shuichi Kawashiri (Kanazawa University)H-Index: 22
view all 8 authors...
PURPOSE The incidence of obstructive sleep apnea (OSA) immediately after surgery in patients with dentofacial deformities without previous OSA remains unknown. We aimed to perioperatively evaluate factors associated with oxygen desaturation index (ODI) during sleep, 7 days after bilateral splitting ramus osteotomy (BSSRO) in patients without previous OSA. METHODS Fifty-one patients (15 males, 36 females) with dentofacial deformities, scheduled to undergo BSSRO, were included. Polysomnography was...
Source
#1Mohiuddin (Kanazawa University)H-Index: 1
#2Kazuo Kasahara (Kanazawa University)H-Index: 26
Abstract The coronavirus disease 2019 (COVID-19) pandemic has triggered a sudden global change in healthcare systems. Cancer patients have a higher risk of death from COVID-19 in comparison to patients without cancer. Many studies have stated that various factors, such as older age, frequent exposure to healthcare, and higher smoking rates are responsible for the complications of COVID-19. We hypothesize that side effects of chemotherapy, such as cellular senescence, could worsen COVID-19. Given...
Source
#1M D Mohiuddin (Kanazawa University)
#2Kazuo Kasahara (Kanazawa University)H-Index: 26
Background/aim Cisplatin is a potent anticancer drug for treating several types of cancer, including non-small-cell lung cancer (NSCLC). In this study, we investigated the cytotoxicity and mechanism of action of cisplatin in the human NSCLC cell line PC9. Materials and methods PC9 cells were treated with cisplatin for 72 h and then evaluated by a cell viability assay, DAPI staining, Giemsa staining, apoptosis assay, membrane permeability assay, cell cycle assay, ROS assay, SA-β-gal staining, TUN...
Source
#1Toshiyuki KitaH-Index: 15
#2Tomoyuki ArayaH-Index: 7
Last. Kazuo Kasahara (Kanazawa University)H-Index: 26
view all 6 authors...
Abstract A 79-year-old woman was diagnosed with stage IV (cT1aN1M1, OSS) lung adenocarcinoma with bone metastasis of the right femur. She received nivolumab as a third-line treatment. She developed pain in the right shoulder, left wrist, right knee, and waist as well as a low-grade fever and morning stiffness, after five courses of nivolumab. After closer examination, she was diagnosed with polymyalgia rheumatica (PMR) precipitated by an immune-related adverse event. Nivolumab was discontinued, ...
Source
#1Hayato Koba (Kanazawa University)H-Index: 5
#2Hideharu Kimura (Kanazawa University)H-Index: 21
Last. Kazuo Kasahara (Kanazawa University)H-Index: 26
view all 9 authors...
In cancer patients, circulating cell-free DNA (cfDNA) includes tumor-derived DNA (tDNA). cfDNA has been used clinically for non-invasive gene mutation testing. The aim of this study was to characterize the features of the genetic alterations detected in cfDNA. This study included 6 patients with primary lung cancer who died due to cancer progression. Tumors were biopsied at autopsy. Genetic alteration profiles were obtained using next generation sequencing. The features of the tDNA genetic alter...
Source
#1Mohiuddin (Kanazawa University)H-Index: 1
#2Kazuo Kasahara (Kanazawa University)H-Index: 26
Background: Paclitaxel is used as first-line and subsequent therapy for the treatment of various cancers. However, the mechanisms by which paclitaxel exerts its anticancer activity against non-small cell lung cancer (NSCLC) are not well understood. This study aimed to investigate paclitaxel9s role in cell proliferation, apoptosis, and cellular senescence of PC9-MET (gefitinib-resistant) cells and reveal the underlying mechanisms. Methods: PC9-MET cells were treated with paclitaxel for 72 h and t...
Source
#1Mohiuddin (Kanazawa University)H-Index: 1
#2Kazuo Kasahara (Kanazawa University)H-Index: 26
Background: For cancer patients9 treatment, coronavirus disease 2019 (COVID-19) poses a great challenge. COVID-19 presents as a severe respiratory infection in aging individuals, including patients with lung cancer. COVID-19 may be linked to the progression of aggressive lung cancer. Conversely, chemotherapy9s side effects, such as chemotherapy resistance, acceleration of cellular senescence, could worsen COVID-19. Considering the above-mentioned facts, our present work was aimed to investigate ...
1 CitationsSource